Noninvasive Cancer Diagnostics Market: By Product (Tests Kits & Reagents and Consumables) By Application (Lung Cancer, Breast Cancer, Solid tumors, Blood cancer, Others), By Technique (Immunochemistry/Immunoassay, Molecular Diagnostics, Clinical Chemistry, and Others), By Distribution Channel (Hospitals, Diagnostic Center, Oncology Centers and Others) and By Geography

Purchase Option

$ 4400
$ 6600
$ 8900

Noninvasive Cancer Diagnostics Market size was valued at USD 193.2 billion in 2022, growing at a CAGR of 7.4% from 2023 to 2029. The noninvasive technique is a procedure that does not require insertion of an instrument through the skin. With the advancements in the technology, there are various treatment procedures that are being used. The advent of the modern diagnostic techniques helps in the detection of cancer. The noninvasive techniques play a vital role in the diagnosis of cancer replacing the invasive tests. Noninvasive Cancer Diagnostics Market is a method of diagnosing a condition that does not require or requires only minor body incisions. These techniques include determining genetic structure, biomarkers, alterations in molecular biology, and imaging technologies, among others. Cancer is a disease caused by a genetic change in the cells, resulting in uncontrolled development and the formation of a tumor-like structure. Imaging is the primary method of cancer detection, but it does not allow for genetic access; on the other hand, biopsies that allow for genetic access are complicated and difficult to do repeatedly during cancer diagnosis and treatment. As a result, innovative approaches such as molecular diagnostics, serum-based immunoassays, and chemical tests have been developed to identify chemical components in the body, particularly from blood and urine.

 

Noninvasive Cancer Diagnostics Market Key Developments:
  • In February 2020, Biocare Medical launched its seven new IVD IHC antibody markers, especially for clinical diagnostics and research applications, focusing on various immuno-oncology markers, vital in aiding early-stage cancer patient treatment and drug developments. This launch will help the company to enhance its product portfolio in the market.

Noninvasive Cancer Diagnostics Market Summary

Study Period

2024-2030

Base Year

2023

CAGR

7.4%

Largest Market

North America

Fastest Growing Market

North America

Noninvasive Cancer Diagnostics Market Dynamics

Increase in the prevalence of chronic diseases such as cancer is the key factor attributed for the growth of the noninvasive cancer diagnostics market. The technological advancements play a vital role in the development of the noninvasive techniques. Rising demand for the noninvasive and minimally invasive diagnosis is adding fuel for the growth of the market. The growing geriatric population along with growing health issues and rising awareness among the patient population regarding various treatment options is boosting the growth of the noninvasive cancer diagnostics market. The initiation taken by the government and non-profitable organizations to create awareness regarding the early diagnosis of the disease is anticipated to drive the growth of the noninvasive cancer diagnostics market.

Noninvasive Cancer Diagnostics Market Segmentation

By Product

  • Test Kits & Reagents
  • Consumables

By Application

  • Lung Cancer
  • Breast Cancer
  • Solid tumors
  • Blood cancer
  • Others

By Technique

  • Immunochemistry/Immunoassay
  • Molecular Diagnostics
  • Clinical Chemistry
  • Others

By Distribution Channel

  • Hospitals
  • Diagnostic Centers
  • Oncology Centers
  • Others

Frequently Asked Questions

The major factors driving the market growth are the increasing prevalence of various types of cancer, such as lung cancer, breast cancer, and more. Also, the increasing geriatric population and increasing awareness about the diagnosis procedures will be anticipated to expand the market of noninvasive cancer diagnostics.

The high cost of treatment and stringent regulatory policies are some restraining factors that obstruct the market’s growth.

The global noninvasive cancer diagnostics market size is expected to be valued at USD 193.2 billion in 2021.

Investment and acquisition are the two key strategies opted for prominent companies in the market.

Key Features of the Report

  • The noninvasive cancer diagnostics market report provides granular level information about the market size, regional market share, historic market (2018 to 2022) and forecast (2023 to 2029)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments and startup’s details that are actively working in the market
  • The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
  • The report analyses the impact of socio-political environment through PESTLE Analysis and competition through Porter’s Five Force Analysis in addition to recent technology advancements and innovations in the market
1.Executive Summary
2.Global Noninvasive Cancer Diagnostics Market Introduction 
2.1.Global Noninvasive Cancer Diagnostics Market  - Taxonomy
2.2.Global Noninvasive Cancer Diagnostics Market  - Definitions
2.2.1.Product
2.2.2.Application
2.2.3.Technique
2.2.4.Distribution Channel
2.2.5.Region
3.Global Noninvasive Cancer Diagnostics Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Product Landscape
3.6. New Product Launches
3.7. Impact of COVID 19 on Market
4.Global Noninvasive Cancer Diagnostics Market Analysis, 2018-2022 and Forecast 2023-2029
4.1.  Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
4.2.  Year-Over-Year (Y-o-Y) Growth Analysis (%) 
4.3.  Market Opportunity Analysis 
5.Global Noninvasive Cancer Diagnostics Market By Product, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
5.1. Test Kits & Reagents
5.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.1.3. Market Opportunity Analysis 
5.2. Consumables
5.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.2.3. Market Opportunity Analysis 
6.Global Noninvasive Cancer Diagnostics Market By Application, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
6.1. Lung Cancer
6.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.1.3. Market Opportunity Analysis 
6.2. Breast Cancer
6.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.2.3. Market Opportunity Analysis 
6.3. Solid tumors
6.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.3.3. Market Opportunity Analysis 
6.4. Blood cancer
6.4.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
6.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.4.3. Market Opportunity Analysis 
6.5. Others
6.5.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
6.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.5.3. Market Opportunity Analysis 
7.Global Noninvasive Cancer Diagnostics Market By Technique, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
7.1. Immunochemistry/Immunoassay
7.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.1.3. Market Opportunity Analysis 
7.2. Molecular Diagnostics
7.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.2.3. Market Opportunity Analysis 
7.3. Clinical Chemistry
7.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.3.3. Market Opportunity Analysis 
7.4. Others
7.4.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
7.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.4.3. Market Opportunity Analysis 
8.Global Noninvasive Cancer Diagnostics Market By Distribution Channel, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
8.1. Hospitals
8.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.1.3. Market Opportunity Analysis 
8.2. Diagnostic Centers
8.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.2.3. Market Opportunity Analysis 
8.3. Oncology Centers
8.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.3.3. Market Opportunity Analysis 
8.4. Others
8.4.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
8.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.4.3. Market Opportunity Analysis 
9.Global Noninvasive Cancer Diagnostics Market  By Region, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
9.1. North America
9.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
9.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
9.1.3. Market Opportunity Analysis 
9.2. Europe
9.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
9.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
9.2.3. Market Opportunity Analysis 
9.3. Asia Pacific (APAC)
9.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
9.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
9.3.3. Market Opportunity Analysis 
9.4. Middle East and Africa (MEA)
9.4.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
9.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
9.4.3. Market Opportunity Analysis 
9.5. Latin America
9.5.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
9.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
9.5.3. Market Opportunity Analysis 
10.North America Noninvasive Cancer Diagnostics Market ,2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
10.1. Product Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.1.1.Test Kits & Reagents
10.1.2.Consumables
10.2.  Application Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.2.1.Lung Cancer
10.2.2.Breast Cancer
10.2.3.Solid tumors
10.2.4.Blood cancer
10.2.5.Others
10.3.  Technique Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.3.1.Immunochemistry/Immunoassay
10.3.2.Molecular Diagnostics
10.3.3.Clinical Chemistry
10.3.4.Others
10.4.  Distribution Channel Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.4.1.Hospitals
10.4.2.Diagnostic Centers
10.4.3.Oncology Centers
10.4.4.Others
10.5.  Country Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.5.1.United States of America (USA)
10.5.2.Canada
11.Europe Noninvasive Cancer Diagnostics Market ,2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
11.1. Product Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.1.1.Test Kits & Reagents
11.1.2.Consumables
11.2.  Application Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.2.1.Lung Cancer
11.2.2.Breast Cancer
11.2.3.Solid tumors
11.2.4.Blood cancer
11.2.5.Others
11.3.  Technique Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.3.1.Immunochemistry/Immunoassay
11.3.2.Molecular Diagnostics
11.3.3.Clinical Chemistry
11.3.4.Others
11.4.  Distribution Channel Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.4.1.Hospitals
11.4.2.Diagnostic Centers
11.4.3.Oncology Centers
11.4.4.Others
11.5.  Country Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.5.1.Germany
11.5.2.France
11.5.3.Italy
11.5.4.United Kingdom (UK)
11.5.5.Spain
11.5.6.Rest of EU
12.Asia Pacific (APAC) Noninvasive Cancer Diagnostics Market ,2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
12.1. Product Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.1.1.Test Kits & Reagents
12.1.2.Consumables
12.2.  Application Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.2.1.Lung Cancer
12.2.2.Breast Cancer
12.2.3.Solid tumors
12.2.4.Blood cancer
12.2.5.Others
12.3.  Technique Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.3.1.Immunochemistry/Immunoassay
12.3.2.Molecular Diagnostics
12.3.3.Clinical Chemistry
12.3.4.Others
12.4.  Distribution Channel Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.4.1.Hospitals
12.4.2.Diagnostic Centers
12.4.3.Oncology Centers
12.4.4.Others
12.5.  Country Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.5.1.China
12.5.2.India
12.5.3.Australia and New Zealand (ANZ)
12.5.4.Japan
12.5.5.Rest of APAC
13.Middle East and Africa (MEA) Noninvasive Cancer Diagnostics Market ,2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
13.1. Product Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.1.1.Test Kits & Reagents
13.1.2.Consumables
13.2.  Application Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.2.1.Lung Cancer
13.2.2.Breast Cancer
13.2.3.Solid tumors
13.2.4.Blood cancer
13.2.5.Others
13.3.  Technique Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.3.1.Immunochemistry/Immunoassay
13.3.2.Molecular Diagnostics
13.3.3.Clinical Chemistry
13.3.4.Others
13.4.  Distribution Channel Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.4.1.Hospitals
13.4.2.Diagnostic Centers
13.4.3.Oncology Centers
13.4.4.Others
13.5.  Country Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.5.1.GCC Countries
13.5.2.South Africa
13.5.3.Rest of MEA
14.Latin America Noninvasive Cancer Diagnostics Market ,2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
14.1. Product Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
14.1.1.Test Kits & Reagents
14.1.2.Consumables
14.2.  Application Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
14.2.1.Lung Cancer
14.2.2.Breast Cancer
14.2.3.Solid tumors
14.2.4.Blood cancer
14.2.5.Others
14.3.  Technique Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
14.3.1.Immunochemistry/Immunoassay
14.3.2.Molecular Diagnostics
14.3.3.Clinical Chemistry
14.3.4.Others
14.4.  Distribution Channel Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
14.4.1.Hospitals
14.4.2.Diagnostic Centers
14.4.3.Oncology Centers
14.4.4.Others
14.5.  Country Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
14.5.1.Brazil
14.5.2.Mexico
14.5.3.Rest of LA
15. Competition Landscape
15.1.  Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) 
15.2.1.Digene Corporation (U.S.)
15.2.2.Gen-Probe Incorporated (U.S.)
15.2.3.IVDiagnostics, Inc. (U.S.)
15.2.4.A&G Pharmaceutical, Inc. (U.S.)
15.2.5.Affymetrix Inc. (U.S.)
15.2.6.AVIVA Biosciences Corporation (U.S.)
15.2.7.BIOVIEW Inc. (U.S.)
15.2.8.Laboratory Corporation of America Holdings (LabCorp) (U.S.)
15.2.9.Quest Diagnostics Incorporated Cancer Genetics Inc. (U.S.)
16. Research Methodology 
17. Appendix and Abbreviations 

 

  • Digene Corporation (U.S.)
  • Gen-Probe Incorporated (U.S.)
  • IVDiagnostics, Inc. (U.S.)
  • A&G Pharmaceutical, Inc. (U.S.)
  • Affymetrix Inc. (U.S.)
  • AVIVA Biosciences Corporation (U.S.)
  • BIOVIEW Inc. (U.S.)
  • Laboratory Corporation of America Holdings (LabCorp) (U.S.)
  • Quest Diagnostics Incorporated Cancer Genetics Inc. (U.S.)

Adjacent Markets